fda approved semaglutide compounding pharmacy warns about compounded versions of semaglutide, used for diabetes, weight loss Hims & Hers stock falls

Practical Guidance for Monitoring and Risk Assessment In everyday clinical practice, how should providers approach these resting heart rate changes

As the prevalence of obesity continues to rise worldwide, GLP-1 receptor agonists such as Ozempic and Wegovy have gained significant attention from both healthcare professionals and patients seeking clinically proven, non-surgical weight loss solutions

Work with us to build your next medical product liability case

deficiency Lancet

Image Credit: joshya/Shutterstock Causes There are three major causes of insufficient platelets in thrombocytopenia

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight